Rockefeller Capital Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$97.7K Buy
928
+402
+76% +$37.4K ﹤0.01% 3088
2026
Q2
$39.4K Sell
526
-365
-41% -$23.4K ﹤0.01% 3472
2026
Q1
$50.2K Buy
891
+13
+1% +$847 ﹤0.01% 3272
2025
Q4
$70.4K Buy
878
+870
+10,875% +$58.5K ﹤0.01% 2903
2025
Q3
$390 Buy
+8
New +$495 ﹤0.01% 4300
2023
Q1
– Sell
-13
Closed -$1K – 2795
2022
Q4
$1K Buy
+13
New +$1.04K ﹤0.01% 3689
2022
Q3
– Sell
-386
Closed -$25K – 4079
2022
Q2
$25K Buy
386
+333
+628% +$19.7K ﹤0.01% 2618
2022
Q1
$3K Buy
53
+3
+6% +$163 ﹤0.01% 3501
2021
Q4
$2K Sell
50
-3
-6% -$183 ﹤0.01% 3539
2021
Q3
$3K Buy
53
+30
+130% +$1.89K ﹤0.01% 3341
2021
Q2
$1K Sell
23
-7
-23% -$495 ﹤0.01% 3333
2021
Q1
$3K Sell
30
-12
-29% -$1.48K ﹤0.01% 3020
2020
Q4
$4K Buy
+42
New +$4.52K ﹤0.01% 2490
2019
Q4
– Sell
-70
Closed -$9K – 2114
2019
Q3
$9K Hold
70
– – ﹤0.01% 1454
2019
Q2
$8K Buy
70
+50
+250% +$4.92K ﹤0.01% 1312
2019
Q1
$2K Buy
+20
New +$1.82K ﹤0.01% 1786

Other funds holding HAE

Rockefeller Capital Management's HAE Position: Q3 2026 in Review

Rockefeller Capital Management increased its Haemonetics (HAE) stake by 76% in Q3 2026, buying an estimated $37.4K and bringing the position to 928 shares worth $97.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3088.

Rockefeller Capital Management first reported a position in HAE in Q1 2019 and has held it in 16 quarters since. 354 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

  • Rockefeller Capital Management held 928 shares of Haemonetics worth $97.7K as of Q3 2026.
  • Rockefeller Capital Management bought 402 Haemonetics shares in Q3 2026, an estimated $37.4K.
  • Haemonetics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3088 holding.
  • Rockefeller Capital Management first reported a position in Haemonetics in Q1 2019 and has held it in 16 quarters since.
  • 354 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.